HTD 1805
Alternative Names: HTD-1805Latest Information Update: 13 Apr 2023
At a glance
- Originator HighTide Biopharma
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Metabolic disorders
Most Recent Events
- 13 Apr 2023 Preclinical trials in Metabolic disorders in China (unspecified route) (HighTide Biopharma pipeline, April 2023).
- 04 Jan 2023 Early research in Metabolic disorders in China (unspecified route) before January 2023 (HighTide Biopharma pipeline, January 2023)